|
Scritto da Critical Care
|
 In our retrospective observational study, carperitide had higher improvement rate of functional class, though some reports have been against the use of nesiritide in acute heart failure patients. Also, the use of carperitide was not associated with death or heart failure admission after adjustment. Carperitide compares favorably to nesiritide in several ways; it has a shorter half-life, does not mandate bolus infusion, and used mostly as a single agent. We surmise that these unique pharmacological profiles may be part of the reasons for the difference in outcomes and the use of carperitide should be judiciously evaluated in prospective trials.Key words: carperitide, nesiritide, acute heart failure
Fonte: Critical Care |
